Afatinib in Patients with Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1/PHASE2

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-11-08

Study Completion Date

2028-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This research study is a phase Ib/II, single-arm, non-randomized, non-blind, multicenter study designed to determine whether Afatinib is effective and safe in patients with locoregionally unresectable and / or metastatic HNSCC with Fanconi Anemia.

The main hypothesis, based on preclinical evidence, is that treatment with afatinib, an epithelial growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), could be an effective treatment option to control cancer for patients with FA - HNSCC.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Afatinib Plus Chemotherapy Against Esophageal or Lung Squamous Cell Carcinoma

NCT03486509

Squamous Cell Carcinoma

UNKNOWN PHASE2

Afatinib in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification (ESCC-A01)

NCT03940976

Esophageal Squamous Cell Carcinoma

UNKNOWN PHASE2

Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation

NCT02208843

Carcinoma, Non-Small-Cell Lung

COMPLETED PHASE4

To Evaluate the Efficacy and Safety of Afatinib for Advanced ALTRK-negative ESCC

NCT05818982

Advanced Esophageal Squamous Cell Carcinoma

RECRUITING PHASE2

Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma

NCT05070403

Squamous Cell Carcinoma

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fanconi Anemia Head and Neck Squamous Cell Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Afatinib

Afatinib starting at 20 mg (weeks 1-2), escalating to 30 mg after two weeks (weeks 3-4) and escalating to 40 mg after one month (week 5 - thereafter) if no hematologic or other relevant toxicities are observed (CTCAE V5.0 \< grade 2)

Group Type EXPERIMENTAL

Afatinib

Intervention Type DRUG

Afatinib starting at 20 mg (weeks 1-2), escalating to 30 mg after two weeks (weeks 3-4) and escalating to 40 mg after one month (week 5 - thereafter) if no hematologic or other relevant toxicities are observed (CTCAE V5.0 \< grade 2)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Afatinib

Afatinib starting at 20 mg (weeks 1-2), escalating to 30 mg after two weeks (weeks 3-4) and escalating to 40 mg after one month (week 5 - thereafter) if no hematologic or other relevant toxicities are observed (CTCAE V5.0 \< grade 2)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Written informed consent according to local guidelines, must be signed and dated by the participant and investigator prior to performing any protocol procedure.
2. Patient is ≥ 18 years of age.
3. Confirmed diagnosis of Fanconi anemia.
4. Histologically or cytologically confirmed unresectable or locoregionally advanced squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, larynx, nasopharynx, paranasal sinuses or salivary glands. Patients with distal metastasis (M1, American Joint Cancer Committee (AJCC) 8th ed.) are also eligible.
5. Tumor not a candidate for resection prior to Afatinib due to technical inability to resect (tumor fixation / invasion in the skull base, cervical vertebrae, nasopharynx or fixed lymph nodes) and / or low surgical cure \[T3-T4, N2-N3; , AJCC 8th ed.\]).
6. Patients must have at least 1 measurable lesion by computed tomography (CT) scan or magnetic resonance imaging (MRI) as defined by RECIST v1.1.
7. Previous anticancer treatment is allowed if it ends 6 weeks or 5 half-lives, whichever is shorter, before the expected date of start of the study treatment.
8. Previous locoregional treatments such as radiotherapy are allowed.
9. Eastern Cooperative Oncology Group (ECOG) performance status \< 2 at inclusion.
10. Adequate organ and bone marrow functions, as defined below:

1. Neutrophils \> 1000 cells / microliter.
2. Platelets \> 50,000 cells / microliter.
3. Hemoglobin \> 8 g / dL
4. Creatinine \< 1.5 x upper limit normal (ULN) with clearance \> 50 mL / min.
5. Total bilirubin \< 1.5 x ULN. Note: patients with Gilbert's may be included with bilirubin \<2 x ULN.
6. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 2.5 x ULN or \< 5 ULN if liver metastases are present.
7. International normalized ratio (INR) and prothrombin time (PT) \<1.5 x ULN.
11. Female patients must either:

1. Be of non-childbearing potential:

Postmenopausal \*(defined as at least 1 year without any menses) prior to screening , or Documented surgically sterile (e.g.hysterectomy, bilateral salpingectomy, bilateral oophorectomy, or bilateral tubal occlusion).

\*Those who are amenorrheic due to an alternative medical cause are not considered postmenopausal and must follow the criteria for childbearing potential subjects.

OR
2. If of childbearing potential:

Agree not to try to become pregnant during the study and for at least 1 months after the final study drug administration, And have a negative urine or serum pregnancy test within 7 days prior to Day 1 (females with false positive results and documented verification of negative pregnancy status are eligible for participation), And if heterosexually active, agree to abstinence (if in line with the usual preferred lifestyle of the patient) or consistently use a condom plus 1 form of highly effective birth control per locally accepted standards starting at screening and throughout the study period and for at least 1 month after the final study drug administration.
12. Female patients must agree not to breastfeed or donate ovules starting at screening and throughout the study period, and for at least 1 month after the final study drug administration.
13. Male patients must not donate sperm starting at screening and throughout the study period, and for at least 1 month after the final study drug administration.
14. Male patients with a partner with childbearing potential, or who is pregnant or breastfeeding must agree to abstinence or use a condom plus 1 form of highly effective birth control throughout the study period and for at least 1 month after the final study drug administration.
15. Patient agrees not to participate in another interventional study while on treatment in the present study.

Exclusion Criteria

1. Patients who are candidates for surgery with curative intent are not eligible.
2. Less than two weeks from surgical resection or other major surgical procedure at start of treatment. Planned surgery for other diseases.
3. Previous treatment with EGFR small molecule inhibitors, EGFR inhibitory antibodies and / or any investigational agents for the treatment of HNSCC within 4 weeks prior to the selection was not allowed.

Note: Previous treatment with chemotherapy and/or radiotherapy is allowed.
4. Patient must have recovered from any previous treatment toxicity to Grade ≤ 2.
5. Existence of any other intercurrent malignant disease is not allowed within the previous 2 years to inclusion.

Note: Patients with non melanoma skin cancer, curatively treated localized prostate cancer, or carcinoma in situ of any type (if complete resection was performed) are allowed.
6. Active severe Severe infectious disease in the 4 weeks prior to the initiation of study treatment, including . Known human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C.
7. Patient has documented history of a cerebral vascular event (stroke or transient ischemic attack), or the following criteria for cardiac disease:

1. Myocardial infarction or unstable angina pectoris within 6 months of enrollment.
2. History of serious ventricular arrhythmia (ie, ventricular tachycardia or ventricular fibrillation), high-grade atrioventricular block, or other cardiac arrhythmias requiring antiarrhythmic medications (except for atrial fibrillation that is well controlled with antiarrhythmic medication); history of QT interval prolongation.
3. New York Heart Association (NYHA) class III or greater congestive heart failure or left ventricular ejection fraction of \< 40%.
8. Participants with QTc interval (corrected) \> 470 msec at screening.
9. History of interstitial lung disease requiring corticosteroids or pneumonitis.
10. Gastrointestinal disorders that may interfere with the absorption of the study drug or chronic diarrhea.
11. Patient has known hypersensitivity to afatinib or to any excipient contained in the drug formulation.
12. Female patients who are or intend to be pregnant or breastfeeding during their participation in the study or 1 month after the final study drug administration.
13. Patients unable to comply with the protocol as determined by the investigator.
14. The patient is currently participating in another clinical trial that would interfere with the radiological imaging schedule or any other determinations required in this protocol.
15. Patient has other underlying medical conditions that, in the opinion of the investigator, would impair the ability of the patient to receive or tolerate the planned treatment and follow-up.
16. Patients with psychiatric disorders that may interfere with monitoring.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No